ASArthur Schmidt

Arthur Schmidt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arthur Schmidt has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Learning curve of endoscopic submucosal dissection (ESD) with prevalence-based indication in unsupervised Western settings: a retrospective multicenter analysis

    by Ingo Steinbrück, Siegbert Faiss, Franz Ludwig Dumoulin, Tsuneo Oyama, Jürgen Pohl, Thomas von Hahn, Arthur Schmidt, Hans-Peter Allgaier

    Background and aims As there is still no consensus about the adequate training strategy for ESD in Western countries, we evaluated unsupervised prevalence-based learning curves including detailed organ-specific subgroup analysis. Methods The first 120 ESDs of four operators (n = 480) were divided into three groups (1: ESD 1–40, 2: ESD 41–80, 3: ESD 81–120). Outcome parameters were rates of technical success, en bloc and R0 resection, the resection speed, rates of conversion to EMR, curative resection, adverse events, surgery due to adverse events, and recurrence. In addition, we analyzed the achievement of quality benchmarks indicating levels of expertise. Results After exclusion of pretreated lesions, 438 procedures were enrolled in the final analysis. Technical success rates were > 96% with significant improvements regarding rate of en bloc resection (from 82.6 to 91.2%), resection speed (from 4.54 to 7.63 cm2/h), and rate of conversion to EMR (from 22.0 to 8.1%). No significant differences could be observed for rates of R0 resection (65.9 vs. 69.6%), curative resection (55.8 vs. 55.7%), adverse events (16.3 vs. 11.7%), surgery due to adverse events (1.5 vs. 1.3%), and recurrence (12.5 vs. 4.5%). Subgroup and benchmark analysis revealed an improvement in esophageal, gastric, and rectal ESD with achievement of competence levels for the esophagus and stomach within 80 and most of the benchmarks for proficiency level within 120 procedures. Some of the benchmarks could also be achieved in rectal ESD. Conclusions This trial confirms safety and feasibility of unsupervised ESD along the initial learning curve with prevalence-based indication and exclusion of colonic cases.


  • Endoscopic full-thickness resection for T1 colorectal cancer: here to stay!

    by Arthur Schmidt

    Even in an era of highly advanced imaging and resection techniques, treatment of T1 colorectal cancer remains a challenge. In clinical practice, we are faced with two problems. First, early cancer is often not recognized as such, and insufficient resection techniques are used, resulting in incomplete polypectomy. In these cases, it is difficult to judge whether there is residual tumor or not and scarring may hamper endoscopic re-therapy. Second, current guidelines recommend oncological surgical resection for patients at high risk of lymph node metastasis, whereas endoscopic treatment is considered to be curative for low-risk tumors. However, this risk assessment is done on the basis of histological features, and we currently do not have endoscopic criteria to reliably classify early tumors prior to treatment. For the patient, this may ultimately result in over- as well as undertreatment. In this issue of Endoscopy, Zwager et al. present a detailed retrospective analysis of 330 cases undergoing endoscopic full-thickness resection (EFTR) for T1 carcinomas [1]. These cases had been recorded in the nationwide Dutch EFTR registry; results of the total cohort, including other indications for EFTR, have been reported previously [2]. The main outcomes of the current study were technical success, R0 resection, possibility of histological risk stratification, rate of curative resection, adverse events, and lesion recurrence. A total of 330 procedures were included, 132 involving primary treatment of suspected or proven T1 carcinoma and 198 involving EFTR after previous incomplete resection. “The potential of EFTR as “excisional biopsy” includes the final determination of R0 status in cases of scar resection, as well as histological assessment of vascular, lymphatic, and submucosal invasion in cases of previously untreated lesions.” Technical success (defined as macroscopic complete en bloc resection) was 87.0 % and is in line with most other studies on EFTR using the full-thickness resection device (Ovesco Endoscopy AG, Tübingen, Germany). More importantly, the R0 resection rate was as high as 85.6 %. This rate is comparable or even higher than that for endoscopic submucosal dissection (ESD) in Western countries [3] [4]. Importantly, the R0 rates did not differ significantly between primary treatment (82 %) and resection of polypectomy scars (88 %). In a very similar study on EFTR for T1 cancer by our group, the R0 rates of the total cohort and especially of the primary treatment group were markedly lower (71.8 % and 60.9 %) [5]. The reasons for this difference are unclear but it is very likely that more advanced lesions were included in our study. This highlights that patient selection is important for successful EFTR and that such criteria need to be defined in future studies. The lesions included in the study were relatively small (median diameter 15 mm for primary resection). At least one previous study indicated that chance of R0 resection may drop with increasing lesion size [6]. I therefore agree with the authors, that T1 lesions with a diameter of > 20 mm should not be selected for EFTR. While more complex resection techniques such as ESD are excellent for the control of lateral margins, they are by definition limited to submucosa. As discussed by the authors, for lesions with deep submucosal invasion, this may result in incomplete resection [7]. The study by Zwager et al. included a significant proportion of patients with sm2 /sm3 tumors and the R0 rate was still excellent. Recent studies have demonstrated that deep submucosal infiltration in the absence of other risk factors is associated with a low prevalence of lymph node metastasis [8]. Hence, complete resection by EFTR may increase the chance for curative endoscopic treatment. Indeed, the authors report an increase of curative resection rates from 23.7 % to 60.8 % when excluding sm2/sm3 infiltration as a risk factor. However, this approach may not be in line with all international guidelines and needs further evaluation. Furthermore, the rate of curative resection may have been overestimated because other risk factors such as tumor budding were not consistently evaluated in the study. Apart from demonstrating effective local treatment for low-risk tumors, the study results highlight the potential of EFTR as “excisional biopsy.” Compared with endoscopic mucosal resection or ESD, a full-thickness specimen is likely to fulfill the pathologist’s needs when it comes to histological assessment of invasive lesions. We do not have any comparative studies, but the study by Kuellmer et al. showed that the exact determination of risk status was possible in > 99 % of cases [5]. This included final determination of R0 status in cases of scar resection, as well as histological assessment of vascular, lymphatic, and submucosal invasion in cases of previously untreated lesions. Interestingly, only 15.3 % of patients in the study were referred for oncological resection due to the presence of one or more high-risk features. This further emphasizes that surgical resections may be avoided by use of EFTR. In the study, a significant proportion of patients who had finally been classified as high-risk after EFTR were not referred to surgery because of co-morbidities and/or patient preference. For patients unfit for surgery, EFTR may provide a minimally invasive local treatment; however, we do not have sufficient data on oncological outcome and therefore cannot finally conclude whether these patients will really benefit from this approach. I would like to stress that as endoscopists we should not only aim to avoid unnecessary surgery. In the current study, histological data were available from 47 oncological resections, which had been performed due to high-risk features in the EFTR specimen. Residual tumor and/or lymph node metastasis was found in 11 cases, corresponding to a rate of 23.4 %. We are...


  • Esophageal lichen planus: towards diagnosis of an underdiagnosed disease

    by Franziska Schauer, Carmen Monasterio, Kristin Technau-Hafsi, Johannes Steffen Kern, Adhara Lazaro, Peter Deibert, Peter Hasselblatt, Henning Schwacha, Steffen Heeg, Volker Brass, et al.

    Background: Although lichen planus (LP) is a common skin disorder, the prevalence of esophageal involvement (ELP) and its clinical manifestations are poorly defined. We aimed to establish diagnostic criteria and characterize disease outcomes of ELP. Methods: Clinical, endoscopic, histological, and immunofluorescence data from consecutive patients with known LP between 2013 and 2018 were analyzed. We established endoscopic (denudation and tearing of the mucosa, hyperkeratosis and trachealization) and histological criteria (mucosal detachment, T-lymphocytic infiltrate, intraepithelial apoptosis, dyskeratosis, and fibrinogen deposits along the basement membrane) to grade disease severity. Endoscopic findings were correlated with clinical symptoms. Response to medical therapy was monitored. Results: Fifty-two consecutive patients (median age 59.5 years) were analyzed. According to our grading system, 16 patients were considered as severe and 18 as mild ELP. Dysphagia was the only symptom which differentiated patients with severe (14/16) or mild ELP (8/18) from patients without ELP (1/18). Concomitant oral and genital involvement of LP was associated with the presence of ELP, while oral involvement alone was not. Follow-up of 14/16 patients with severe EPL for at least one year revealed that most of these patients responded to topical corticosteroids (budesonide: n = 9/10 or fluticasone n = 2/2). Three budesonide patients experienced a resolution of symptomatic esophageal stenosis. Conclusions: Esophageal involvement of LP is frequent, but may be asymptomatic. ELP can be diagnosed using the diagnostic criteria proposed here. Dysphagia and combined oral and genital manifestation are associated with ELP. Therapy with topical corticosteroids appears to be a prudent therapeutic approach for ELP.


  • Open Access

    Effective treatment of benign biliary strictures with a removable, fully covered, self‐expandable metal stent: A prospective, multicenter European study

    by Arthur Schmidt, Tilman Pickartz, Markus M Lerch, Fabrizio Fanelli, Fausto Fiocca, Pierleone Lucatelli, Fabrizio Cereatti, Albrecht Hoffmeister, Werner van Steenbergen, Matthias Kraft, et al.

    Background: Temporary placement of removable, fully covered, self‐expandable metal stents (fcSEMS) for treatment of benign biliary strictures (BBS) has been reported to be effective. However, the optimal extraction time point remains unclear and stent migration has been a major concern.Objective: The objective of this study was to evaluate the efficacy and safety of this treatment modality using an fcSEMS with a special antimigration design and prolonged stent indwell time.Methods: We performed a prospective, single‐arm study at six tertiary care centers in Europe. Patients with BBS underwent endoscopic or percutaneous implantation of an fcSEMS (GORE® VIABIL® Biliary Endoprosthesis, W.L. Gore & Associates, Flagstaff, AZ, USA). The devices were scheduled to be removed nine months later, and patients were to return for follow‐up for an additional 15 months.Results: Forty‐three patients were enrolled in the study. Stricture etiology was chronic pancreatitis in the majority of patients (57.5%). All fcSEMS were placed successfully, either endoscopically (76.7%) or percutaneously (23.3%). Stent migration was observed in two patients (5.2%). Primary patency of the SEMS prior to removal was 73.0%. All attempted stent removals were successful. At removal, stricture was resolved or significantly improved without need for further therapy in 78.9% of patients. Stricture recurrence during a follow‐up of two years post‐implant was observed in two patients.Conclusions: Temporary placement of the fcSEMS is a feasible, safe and effective treatment for BBS. The design of the device used in this study accounts for very low migration rates and facilitates easy stent retrieval, even after it has been in place for up to 11 months.